Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about AVROBIO, INC.
01/07AVROBIO Gets Approval to Cut 23% of Workforce
MT
01/07AVROBIO : Current Report (Form 8-K)
PU
01/06Mizuho Adjusts AVROBIO's Price Target to $6 from $28, Keeps Buy Rating
MT
01/06AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/06NORTH AMERICAN MORNING BRIEFING : Tech Stocks Set -3-
DJ
01/05Morgan Stanley Adjusts Price Target on AVROBIO to $3 From $7, Maintains Equal-Weight Ra..
MT
01/05Needham Adjusts AVROBIO's Price Target to $8 From $28, Reiterates Buy Rating
MT
01/05BTIG Downgrades AVROBIO to Neutral From Buy
MT
01/05Barclays Adjusts AVROBIO's Price Target to $6 From $22, Reiterates Overweight Rating
MT
01/04Ford, Hess rise; Blackbaud, Avrobio fall
AQ
01/04Wedbush Lowers PT for AVROBIO to $14 From $30 As Company 'Deprioritizes' Fabry Disease ..
MT
01/04AVROBIO : Reprioritizes Pipeline Programs - Form 8-K
PU
01/04Avrobio Shifts Focus From Fabry Disease to Lysosomal Disorder; Resumes Activity After B..
MT
01/04AVROBIO : Pipeline Prioritization and Fabry Data Presentation
PU
01/04AVROBIO Reprioritizes Pipeline Programs
BU
01/04AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engra..
CI
2021AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021Avrobio Reports No Adverse Effects for Gene Therapies AVR-RD-01, AVR-RD-02
MT
2021AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Dat..
BU
2021AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safet..
CI
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
2021Morgan Stanley Downgrades AVROBIO to Equal-Weight From Overweight, Adjusts Price Target..
MT
2021Jasper Therapeutics Teams Up with Avrobio To Study JSP191 On Fabry, Gaucher Disease Pat..
MT
2021Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as..
CI
2021AVROBIO to Present at Two Upcoming Investor Conferences in November
BU
2021AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
BU
2021AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update - For..
PU
2021AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
BU
2021AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2021AVROBIO Receives FDA Rare Pediatric Disease Designation for Hunter Syndrome Treatment; ..
MT
2021Avrobio Gets Rare Pediatric Disease Designation for Hunter Syndrome Treatment
DJ
2021AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a ..
BU
2021AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a ..
CI
2021AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Of..
BU
2021AVROBIO, Inc. Announces Appointment of Essra Ridha as Chief Medical Officer
CI
2021AVROBIO : to Present at the Jefferies Virtual Gene Therapy/Editing Summit
BU
2021AVROBIO : Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry ..
PU
2021AVROBIO : Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry ..
BU
2021AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry..
CI
2021AVROBIO : Morgan Stanley Adjusts AVROBIO's Price Target to $25 from $27, Keeps Overweight ..
MT
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : to Present New Clinical and Preclinical Data Across Multiple Programs at the ESG..
BU
2021AVROBIO, Inc. to Present New Clinical and Preclinical Data Across Multiple Programs at ..
CI
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO, INC.(NASDAQGS : AVRO) dropped from S&P Biotechnology Select Industry Index
CI
2021MAGENTA THERAPEUTICS : Gets FDA Clearance for Leukemia Drug Trial, Plans Phase 1/2 Study i..
MT
2021Magenta Therapeutics Gets IND Clearance for MGTA-117
DJ
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : to Participate at Four Upcoming Investor Conferences
BU
2021AVROBIO : Corporate Presentation August 2021
PU
2021UPDATE : Bluebird Bio Shares Slump Amid FDA Clinical Hold for Lenti-D, Plans to Wind Down ..
MT
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635
AQ
2021AVROBIO : Reports Second Quarter 2021 Financial Results and Provides Business Update
BU
2021Avrobio, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO : to Present at Two Upcoming Investor Conferences in August
BU
2021AVROBIO : Morgan Stanley Adjusts Price Target on AVROBIO to $29 From $31, Maintains Overwe..
MT
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
2021AVROBIO, INC.(NASDAQGS : AVRO) added to Russell Microcap Value Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) added to Russell 3000E Value Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) added to Russell Small Cap Comp Value Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) dropped from Russell 2500 Growth Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) dropped from Russell Microcap Growth Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) dropped from Russell 3000E Growth Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) dropped from Russell 3000 Growth Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) added to Russell 2000 Value Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) dropped from Russell 2000 Growth Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) dropped from Russell Small Cap Comp Growth Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) added to Russell 3000 Value Index
CI
2021AVROBIO, INC.(NASDAQGS : AVRO) added to Russell 2500 Value Index
CI
2021AVROBIO : Corporate Presentation June 2021
PU
1  2  3  4  5Next
Upcoming event on AVROBIO, INC.